Cite
APA Citation
Aggarwal, R., Costin, D., Zhang, J., Monk, P., Linch, M., Karsh, L., Healey, D., Corsi-Travali, S., Adurthi, S., Adedoyin, A., & O'Neill, V. (n.d.). 341 Phase 1b/2 study of BXCL701, an oral activator of the systemic innate immunity pathway, combined with pembrolizumab (pembro), in men with metastatic castration-resistant prostate cancer (mCRPC). Journal for immunotherapy of cancer, 8, A366. http://access.bl.uk/ark:/81055/vdc_100144713769.0x000004